Bank of New York Mellon Corp decreased its stake in GRIFOLS S A/S (NASDAQ:GRFS) by 5.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 688,453 shares of the biotechnology company’s stock after selling 40,068 shares during the period. Bank of New York Mellon Corp’s holdings in GRIFOLS S A/S were worth $12,557,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Trellus Management Company LLC acquired a new stake in shares of GRIFOLS S A/S in the second quarter worth $547,000. Assetmark Inc. boosted its stake in GRIFOLS S A/S by 29.8% during the second quarter. Assetmark Inc. now owns 38,993 shares of the biotechnology company’s stock worth $711,000 after buying an additional 8,942 shares in the last quarter. Natixis Advisors L.P. boosted its stake in GRIFOLS S A/S by 6.5% during the second quarter. Natixis Advisors L.P. now owns 64,366 shares of the biotechnology company’s stock worth $1,174,000 after buying an additional 3,949 shares in the last quarter. Black Creek Investment Management Inc. boosted its stake in GRIFOLS S A/S by 1.5% during the second quarter. Black Creek Investment Management Inc. now owns 3,332,249 shares of the biotechnology company’s stock worth $60,780,000 after buying an additional 48,078 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in GRIFOLS S A/S by 70.8% during the second quarter. PNC Financial Services Group Inc. now owns 6,916 shares of the biotechnology company’s stock worth $126,000 after buying an additional 2,867 shares in the last quarter. Institutional investors and hedge funds own 17.98% of the company’s stock.

Shares of GRFS stock opened at $16.62 on Wednesday. The firm has a fifty day moving average of $17.22 and a 200-day moving average of $19.13. The company has a quick ratio of 1.18, a current ratio of 2.86 and a debt-to-equity ratio of 0.97. GRIFOLS S A/S has a 12-month low of $13.40 and a 12-month high of $25.73. The company has a market capitalization of $11.43 billion, a price-to-earnings ratio of 18.47, a P/E/G ratio of 1.00 and a beta of 0.69.

GRIFOLS S A/S (NASDAQ:GRFS) last issued its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.37 by ($0.02). GRIFOLS S A/S had a return on equity of 10.83% and a net margin of 10.40%. The company had revenue of $1.52 billion for the quarter, compared to the consensus estimate of $1.46 billion. On average, equities analysts expect that GRIFOLS S A/S will post 1.29 EPS for the current year.

GRFS has been the subject of a number of analyst reports. Citigroup cut GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a report on Tuesday, June 9th. HSBC raised GRIFOLS S A/S from a “reduce” rating to a “hold” rating in a report on Tuesday, June 9th. Morgan Stanley reaffirmed an “overweight” rating on shares of GRIFOLS S A/S in a report on Tuesday, June 23rd. Zacks Investment Research cut GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Wednesday, August 5th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of GRIFOLS S A/S in a report on Tuesday, July 21st. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. GRIFOLS S A/S currently has a consensus rating of “Hold” and a consensus target price of $24.00.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Further Reading: VIX – Volatility Index

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.